Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

被引：0
|
作者：
Tam, Constantine S.
Simpson, David
Opat, Stephen
Kim, Won Seog
Wang, Michael
Cull, Gavin
Johnston, Patrick B.
Munoz, Javier
Lee, Won-Sik
Marlton, Paula
Gottlieb, David
Wang, Lai
Huang, Jane
Hilger, James
Xue, Ling
Ro, Sunhee
Trotman, Judith
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
152
引用
收藏
页数：3
相关论文
共 50 条
  • [1] BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor
    Li, Na
    Sun, Zhijian
    Liu, Ye
    Guo, Mingming
    Zhang, Yilu
    Zhou, Dongping
    Zhang, Bo
    Su, Dan
    Zhang, Shuo
    Han, Jing
    Gao, Yajuan
    Guo, Yunhang
    Wang, Zhiwei
    Wei, Min
    Luo, Lusong
    Wang, Lai
    CANCER RESEARCH, 2015, 75
  • [2] Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies
    Cull, Gavin
    Opat, Stephen
    Trotman, Judith
    Hilger, James
    Zhang, Xiaoping
    Feng, Shibao
    Ro, Sunhee
    Huang, Jane
    Tam, Constantine S.
    BLOOD, 2017, 130
  • [3] The BTK inhibitor BGB-3111 is synergistic with other anti-lymphoma targeted agents
    Tarantelli, Chiara
    Zhang, Lu
    Curti, Elisabetta
    Spriano, Filippo
    Gaudio, Eugenio
    Cascione, Luciano
    Arribas, Alberto
    Zucca, Emanuele
    Stathis, Anastasios
    Rossi, Davide
    Bertoni, Francesco
    CANCER RESEARCH, 2018, 78 (13)
  • [4] BTK inhibitor BGB-3111 demonstrates anti-tumor activity in solid tumor models
    Hu, Nan
    Zhang, Jiye
    He, Min
    Zhang, Shuo
    Liu, Yong
    Wang, Lai
    CANCER RESEARCH, 2017, 77
  • [5] Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma
    Tam, Constantine S.
    Wang, Michael
    Simpson, David
    Opat, Stephen
    Cull, Gavin
    Munoz, Javier
    Phillips, Tycel J.
    Kim, Won-Seog
    Hilger, James
    Huang, Jane
    Novotny, William
    Trotman, Judith
    BLOOD, 2018, 132
  • [6] Novel Bruton's Tyrosine Kinase Inhibitor Bgb-3111 Demonstrates Potent Activity in Mantle Cell Lymphoma
    Li, Carrie J.
    Liu, Yang
    Bell, Taylor
    Wang, Jack
    Guo, Hui
    Ahmed, Makhdum
    Zhang, Hui
    Lam, Laura T.
    Nomie, Krystle
    Wang, Lai
    Zhang, Liang
    Wang, Michael
    BLOOD, 2016, 128 (22)
  • [7] Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial
    Song, Yuqin
    Zhou, Keshu
    Zou, Dehui
    Zhou, Jianfeng
    Hu, Jianda
    Yang, Haiyan
    Zhang, Huilai
    Ji, Jie
    Xu, Wei
    Jin, Jie
    Lv, Fangfang
    Feng, Ru
    Gao, Sujun
    Zhou, Daobin
    Guo, Haiyi
    Wang, Aihua
    Hilger, James
    Huang, Jane
    Novotny, William
    Osman, Muhtar
    Zhu, Jun
    BLOOD, 2018, 132
  • [8] Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
    Li, Carrie J.
    Jiang, Changying
    Liu, Yang
    Bell, Taylor
    Ye, Yin
    Huang, Shengjian
    Guo, Hui
    Zhang, Hui
    Wang, Lai
    Wang, Jing
    Nomie, Krystle
    Zhang, Liang
    Wang, Michael
    Ma, Wencai
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 267 - 277
  • [9] Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
    Wang, Xianhuo
    Fei, Yue
    Liu, Xia
    Zhang, Tingting
    Li, Wei
    Jia, Xiaohui
    Liu, Xianming
    Qiu, Lihua
    Qian, Zhengzi
    Zhou, Shiyong
    Ren, Xiubao
    Zhai, Qiongli
    Meng, Bin
    Li, Lanfang
    Zhang, Huilai
    AGING-US, 2021, 13 (17): : 21102 - 21121
  • [10] Twice Daily Dosing With the Highly Specific BTK Inhibitor, BGB-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated With Durable Responses in Patients (pts) With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 11 - 12
12345